Tezepelumab for nasal polyps study
Treatments studied
This study looks at how well tezepelumab, a new biologic medicine, works in real life for adults with chronic sinusitis and nasal polyps. It may help reduce symptoms like congestion and runny nose, and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need to have had nasal polyps and chronic sinusitis for at least 12 months.
- You must have a recent SNOT-22 questionnaire score of 30 or higher (this measures how much your symptoms affect you).
- You must have been treated for your condition for at least 30 days, as per the Japanese guidelines.
- Your doctor has to think you are a good candidate for tezepelumab, based on the approved label and guidelines.
- You cannot have had any biologic therapy for asthma or nasal polyps before.
- You must be willing to complete questionnaires and sign the consent form.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tezepelumab, a new injectable medicine, can help reduce nasal polyps and improve symptoms like nasal congestion, loss of smell, and sleep problems. You would receive the study drug while continuing your current nasal steroid spray, and your doctors would track how your symptoms change.
This trial tests a new biologic drug (tezepelumab) to see if it improves symptoms in people with both chronic sinusitis with nasal polyps and severe asthma. The goal is to reduce inflammation and help you breathe better. Participants must not have had prior sinus surgery.
This study looks at how “biologic” medicines work in real-life care for people with severe chronic rhinosinusitis with nasal polyps (CRSwNP). It may help confirm which patients benefit and how treatment is used in everyday practice.
This study looks at why some people with severe chronic nasal polyps respond better to mepolizumab. It may help doctors predict who will benefit from the medicine, and who may need a different plan.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This study follows patients with chronic rhinosinusitis with nasal polyps (CRSwNP)—a condition causing blocked sinuses and nasal growths—who are starting a new biologic medication called tezepelumab. Researchers will track how symptoms and quality of life improve over time in everyday medical practice.
Hear when a new Chronic Rhinosinusitis With Nasal Polyps trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.